Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.42 |
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.42 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.41 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.41 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.41 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.39 |
| ▸ | RRM1 | P23921 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.35 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15148457 | 0.85 | DPP7 (0.41) | DPP7GNAI3GNAO1GNAI1CPB2 | |
| SCHEMBL18235900 | 0.84 | NOD1 (0.41) | DPP7NOD1GNAI3GNAO1GNAI1 | |
| SCHEMBL23280941 | 0.83 | NOD1 (0.40) | DPP7NOD1GNAI3GNAO1GNAI1 | |
| SCHEMBL27900093 | 0.83 | KDM4E (0.48) | DPP7NOD1GNAI3GNAO1GNAI1 | |
| SCHEMBL594596 | 0.83 | KDM4E (0.48) | DPP7NOD1GNAI3GNAO1GNAI1 | |
| SCHEMBL12643957 | 0.83 | KDM4E (0.48) | DPP7NOD1GNAI3GNAO1GNAI1 | |
| SCHEMBL19223347 | 0.81 | TDP1 (0.46) | CPB2KISS1RPOLBKMT2A | |
| Hydrochloric Acid SCHEMBL28854821 | 0.81 | KDM4E (0.47) | DPP7NOD1GNAI3GNAO1GNAI1 | |
| Hydrochloric Acid SCHEMBL28854822 | 0.81 | KDM4E (0.47) | DPP7NOD1GNAI3GNAO1GNAI1 | |
| SCHEMBL11296849 | 0.81 | NOD1 (0.52) | DPP7NOD1GNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025866-A1 | SYNTHESIS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS | NOVARTIS AG (CH) | 2024-01-25 | — | — | US | disclosed |
| US-20240018099-A1 | SYNTHESIS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS | NOVARTIS AG (CH) | 2024-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025866-A1 | SYNTHESIS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS | FOLH1, KLK3, BPHL | DPP7 715/4885NOD1 4531/4885GNAI3 787/4885 |
| US-20240018099-A1 | SYNTHESIS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS | FOLH1, KLK3, BPHL | DPP7 715/4885NOD1 4531/4885GNAI3 787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.